Table 2.
Characteristics of clinical trials
| First author; year | Location | Number of experimental group | Number of control group | Male/female | Type and source of stem cells | Way of stem cells administrated | Doses of stem cells | Times of treatment | Treatment course | Time of following-up | MINORS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liang; 2012 [44] | China | 4 | NA | 3/1 | Allogeneic MSC | Intravenous infusions | 1 × 106/kg body weight | 1 | N/A | 3 months | 8 |
| Hasselblatt; 2012 [45] | Germany | 8 | NA | 7/1 | Autologous HSC | Intravenous infusions | 5.78 × 106/kg body weight | 1 |
Mobilization: 17.8 days Transplantation: 9.8 days |
3.1 years | 11 |
| Dhere; 2016 [46] | USA | 12 | 4 | 6/6 |
Autologous BM-MSC |
Intravenous infusions | 2 × 106, 5 × 106, 10 × 106/kg body weight | 1 | N/A | 9 weeks | 13 |
| Duijvestein; 2010 [47] | The Netherlands | 7 | NA | 1/6 |
Autologous BM-MSC |
Intravenous infusions | 1–2 × 106/kg body weight | 2 | 8 days | 14 weeks | 12 |
| Lopez-Garcia; 2017 [48] | Spain | 22 | NA | 8/14 |
Autologous HSC |
Intravenous infusions | 10 × 106/kg body weight | 1 |
Mobilization: 22 days Transplantation: 27 days |
12 months | 12 |
| Burt; 2010 [49] | USA | 24 | NA | 12/12 |
Autologous HSC |
Intravenous infusions | 6.35 × 106/kg body weight | 1 | Transplantation: 11 days | 5 years | 12 |
| Zhang; 2018 [50] | China | 41 | 41 | 24/17 | Allogeneic UC-MSC | Intravenous infusions | 1 × 106/kg body weight | 4 | 4 weeks | 12 months | 20 |
| Melmed; 2015 [51] | USA | 50 | 16 | NA | PDA-001 | Intravenous infusions | 1.5 × 108, 6 × 108, 12 × 108 | 2 | 8 days | 24 months | 20 |
| Jauregui-Amezaga; 2015 [52] | Spain | 26 | NA | 18/8 |
Autologous HSC |
Intravenous infusions | 14.6 × 106/kg body weight | 1 |
Mobilisation: 18.5 days Transplantation: 26 days |
12 months | 10 |
| Forbes; 2014 [53] | Australia | 15 | NA | 6/9 | Allogeneic BM-MSC | Intravenous infusions | 2 × 106/kg body weight | 4 | 3 weeks | 42 days | 11 |
| Hawkey; 2015 [54] | UK | 23 | NA | 10/13 |
Autologous HSC |
Intravenous infusions | 9 × 106/kg body weight | 1 | NA | 12 months | 22 |
| Mayer; 2014 [55] | USA | 12 | NA | 3/9 | PDA-001 | Intravenous infusions | 2 × 108, 8 × 108 | 2 | 8 days | 12 months | 12 |
| Gregoire; 2018 [56] | Belgium | 13 | NA | 4/9 |
Allogeneic BM-MSC |
Intravenous infusions | 1.5–2.0 × 106/kg body weight | 2 | 4 weeks | 12 weeks | 12 |
| Cassinotti; 2008 [57] | Italy | 4 | NA | 3/1 |
Autologous HSC |
Intravenous infusions | 11 × 106/kg body weight | 1 |
Mobilization: NA Transplantation: 24.5 days |
12 months | 12 |
| Snowden; 2014 [58] | UK | 6 | NA | 3/3 |
Autologous HSC |
Intravenous infusions | NA | 1 | NA | 87 months | 9 |
| Ruiz; 2017 [59] | Brazil | 14 | NA | 7/7 |
Autologous HSC |
Intravenous infusions | 13.4 × 106/kg body weight | 1 | NA | 1 month | 11 |
| Oyama; 2005 [60] | USA | 12 | NA | 6/6 |
Autologous HSC |
Intravenous infusions | 7.7 × 106/kg body weight | 1 |
Mobilization: NA Transplantation: 11 days |
18.5 month | 11 |
| Clerici; 2011 [61] | Italy | 6 | NA | 2/4 |
Autologous HSC |
Intravenous infusions | 10.9 × 106/kg body weight | 1 |
Mobilization: 9 days Transplantation: 13 days |
12 months | 11 |
MSC, mesenchymal stem cells; HSC, hematopoietic stem cell; PDA-001, a preparation of mesenchymal-like adherent cells derived from postpartum placentas; MINORS, methodological index for non-randomized studies; NA, not available; N/A not applicable